These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
78 related articles for article (PubMed ID: 15186828)
1. Novel iodine-124 labeled EGFR inhibitors as potential PET agents for molecular imaging in cancer. Shaul M; Abourbeh G; Jacobson O; Rozen Y; Laky D; Levitzki A; Mishani E Bioorg Med Chem; 2004 Jul; 12(13):3421-9. PubMed ID: 15186828 [TBL] [Abstract][Full Text] [Related]
2. High-affinity epidermal growth factor receptor (EGFR) irreversible inhibitors with diminished chemical reactivities as positron emission tomography (PET)-imaging agent candidates of EGFR overexpressing tumors. Mishani E; Abourbeh G; Jacobson O; Dissoki S; Ben Daniel R; Rozen Y; Shaul M; Levitzki A J Med Chem; 2005 Aug; 48(16):5337-48. PubMed ID: 16078851 [TBL] [Abstract][Full Text] [Related]
3. Novel carbon-11 labeled 4-dimethylamino-but-2-enoic acid [4-(phenylamino)-quinazoline-6-yl]-amides: potential PET bioprobes for molecular imaging of EGFR-positive tumors. Mishani E; Abourbeh G; Rozen Y; Jacobson O; Laky D; Ben David I; Levitzki A; Shaul M Nucl Med Biol; 2004 May; 31(4):469-76. PubMed ID: 15093817 [TBL] [Abstract][Full Text] [Related]
4. Blockage of epidermal growth factor receptor by quinazoline tyrosine kinase inhibitors suppresses growth of human hepatocellular carcinoma. Liu Y; Poon RT; Shao W; Sun X; Chen H; Kok TW; Fan ST Cancer Lett; 2007 Apr; 248(1):32-40. PubMed ID: 16837130 [TBL] [Abstract][Full Text] [Related]
5. Dual irreversible kinase inhibitors: quinazoline-based inhibitors incorporating two independent reactive centers with each targeting different cysteine residues in the kinase domains of EGFR and VEGFR-2. Wissner A; Fraser HL; Ingalls CL; Dushin RG; Floyd MB; Cheung K; Nittoli T; Ravi MR; Tan X; Loganzo F Bioorg Med Chem; 2007 Jun; 15(11):3635-48. PubMed ID: 17416531 [TBL] [Abstract][Full Text] [Related]
6. AEE788: a dual family epidermal growth factor receptor/ErbB2 and vascular endothelial growth factor receptor tyrosine kinase inhibitor with antitumor and antiangiogenic activity. Traxler P; Allegrini PR; Brandt R; Brueggen J; Cozens R; Fabbro D; Grosios K; Lane HA; McSheehy P; Mestan J; Meyer T; Tang C; Wartmann M; Wood J; Caravatti G Cancer Res; 2004 Jul; 64(14):4931-41. PubMed ID: 15256466 [TBL] [Abstract][Full Text] [Related]
7. In silico identification of novel EGFR inhibitors with antiproliferative activity against cancer cells. Cavasotto CN; Ortiz MA; Abagyan RA; Piedrafita FJ Bioorg Med Chem Lett; 2006 Apr; 16(7):1969-74. PubMed ID: 16413185 [TBL] [Abstract][Full Text] [Related]
8. Syntheses and EGFR kinase inhibitory activity of 6-substituted-4-anilino [1,7] and [1,8] naphthyridine-3-carbonitriles. Wissner A; Hamann PR; Nilakantan R; Greenberger LM; Ye F; Rapuano TA; Loganzo F Bioorg Med Chem Lett; 2004 Mar; 14(6):1411-6. PubMed ID: 15006373 [TBL] [Abstract][Full Text] [Related]
9. Design, synthesis, and biological evaluation of aminoboronic acids as growth-factor receptor inhibitors of EGFR and VEGFR-1 tyrosine kinases. Asano T; Nakamura H; Uehara Y; Yamamoto Y Chembiochem; 2004 Apr; 5(4):483-90. PubMed ID: 15185372 [TBL] [Abstract][Full Text] [Related]
10. Synthesis and antitumor evaluation of novel 5-substituted-4-hydroxy-8-nitroquinazolines as EGFR signaling-targeted inhibitors. Jin Y; Li HY; Lin LP; Tan J; Ding J; Luo X; Long YQ Bioorg Med Chem; 2005 Oct; 13(19):5613-22. PubMed ID: 15993078 [TBL] [Abstract][Full Text] [Related]
11. The combi-targeting concept: synthesis of stable nitrosoureas designed to inhibit the epidermal growth factor receptor (EGFR). Domarkas J; Dudouit F; Williams C; Qiyu Q; Banerjee R; Brahimi F; Jean-Claude BJ J Med Chem; 2006 Jun; 49(12):3544-52. PubMed ID: 16759097 [TBL] [Abstract][Full Text] [Related]
12. Synthesis and biological evaluation of bis(methoxy methyl)-7,8-dihydro-[1,4]dioxino[2,3-g]quinazolines as EGFR tyrosine kinase inhibitors. Lee YS; Seo SH; Yang BS; Lee JY Arch Pharm (Weinheim); 2005 Oct; 338(10):502-5. PubMed ID: 16211656 [TBL] [Abstract][Full Text] [Related]
13. Labeled EGFr-TK irreversible inhibitor (ML03): in vitro and in vivo properties, potential as PET biomarker for cancer and feasibility as anticancer drug. Ortu G; Ben-David I; Rozen Y; Freedman NM; Chisin R; Levitzki A; Mishani E Int J Cancer; 2002 Oct; 101(4):360-70. PubMed ID: 12209961 [TBL] [Abstract][Full Text] [Related]
14. The effect of the [18F]-PEG group on tracer qualification of [4-(phenylamino)-quinazoline-6-YL]-amide moiety--an EGFR putative irreversible inhibitor. Dissoki S; Aviv Y; Laky D; Abourbeh G; Levitzki A; Mishani E Appl Radiat Isot; 2007 Oct; 65(10):1140-51. PubMed ID: 17574425 [TBL] [Abstract][Full Text] [Related]